Alpha 2.0
Login Register
» Articles » PMID: 28238745

Seasonal Variability of Severe Asthma Exacerbations and Clinical Benefit from Lebrikizumab

Overview
Journal J Allergy Clin Immunol
Specialty Allergy & Immunology
Date 2017 Feb 28
PMID 28238745
Citations 6
Authors
Tracy L Staton
Joseph R Arron
Julie Olsson
Cecile T J Holweg
John G Matthews
David F Choy
Affiliations
Soon will be listed here.
Citing Articles

Incidence and predictors of asthma exacerbations in middle-aged and older adults: the Rotterdam Study.

de Roos E, Lahousse L, Verhamme K, Braunstahl G, In t Veen J, Stricker B ERJ Open Res. 2021; 7(3).

PMID: 34262968 PMC: 8273296. DOI: 10.1183/23120541.00126-2021.

A Comprehensive Analysis of the Stability of Blood Eosinophil Levels.

Chipps B, Jarjour N, Calhoun W, Iqbal A, Haselkorn T, Yang M Ann Am Thorac Soc. 2021; 18(12):1978-1987.

PMID: 33891831 PMC: 8641810. DOI: 10.1513/AnnalsATS.202010-1249OC.

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.

Corren J, Karpefors M, Hellqvist A, Parnes J, Colice G J Asthma Allergy. 2021; 14:1-11.

PMID: 33469316 PMC: 7810672. DOI: 10.2147/JAA.S286036.

INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics.

McCrae C, Olsson M, Gustafson P, Malmgren A, Aurell M, Fageras M Clin Exp Allergy. 2020; 51(2):273-283.

PMID: 33091192 PMC: 7984268. DOI: 10.1111/cea.13765.

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.

Llanos J, Ortega H, Bogart M, Packnett E, Manjelievskaia J, Bell C J Asthma Allergy. 2020; 13:77-87.

PMID: 32099413 PMC: 6996212. DOI: 10.2147/JAA.S236609.